Clinical trials: Anlotinib
Non-Small-Cell Lung Cancer
Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor cell proliferation related kinase -c-Kit…
- Trial name
- NCT03728374
- Testing
- Anlotinib
- Volunteers
- 38 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Small Cell Lung Cancer
QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer
This is a multicenter, open-label, randomized controlled phase II/III study evaluating the efficacy and safety of QL1706 in combination with anlotinib as later-line treatment in patients with advanced lung cancer.
- Trial name
- NCT07636226
- Testing
- QL1706, Anlotinib
- Volunteers
- 120 people
- Sponsor
- Sun Yat-sen University
NSCLC
Efficacy and Safety of Induction Benmelstobart Plus Anlotinib and Chemotherapy Followed by Concurrent Chemoradiotherapy and Benmelstobart Maintenance Versus Concurrent Chemoradiotherapy Followed by Benmelstobart Maintenance in Patients With Unresectable Stage III NSCLC
The goal of this clinical trial is to compare the efficacy and safety of induction Benmelstobart plus Anlotinib and chemotherapy followed by concurrent chemoradiotherapy (CCRT) and subsequent Benmelstobart maintenance versus CCRT…
- Trial name
- NCT07643350
- Testing
- Benmelstobart, benmelstobart combined with chemotherapy and anlotinib
- Where
- China
- Volunteers
- 152 people
- Sponsor
- The Third Xiangya Hospital of Central South University
Treatment of Recurrent Ovarian Cancer
QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer
Ovarian cancer is one of the most common gynecologic malignancies, with considerable histologic heterogeneity; more than 90 % of cases are epithelial ovarian cancers.
- Trial name
- NCT07286240
- Testing
- QL1706 plus chemotherapy and anlotinib regimen
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Small Cell Lung Cancer Extensive Stage, Resistance to Immunotherapy
Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy
The phase II study enrolled ES-SCLC patients who had disease progression after anti-PD-1/L1 therapy. Participants received intravenous sintilimab 200 mg on day one and oral daily anlotinib 8-12 mg on days 1-14 once every three…
- Trial name
- NCT07022301
- Testing
- sintilimab combined with anlotinib
- Volunteers
- 25 people
- Sponsor
- First Affiliated Hospital of Wannan Medical College
Esophageal Squamous Cell Carcinoma
Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy
Advanced esophageal squamous cell carcinoma patients who have failed first-line PD-1 inhibitor combined with chemotherapy lack a standard treatment option.
- Trial name
- NCT05990231
- Testing
- Cadonilimab combined Anlotinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Pulmonary Pleomorphic Carcinoma, Immunotherapy
Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pulmonary Pleomorphic Carcinoma
Evaluate the efficacy and safety of tislelizumab in combination with anlotinib in patients with stage III and IV PSC .
- Conditions
- Pulmonary Pleomorphic Carcinoma, Immunotherapy, Tislelizumab
- Trial name
- NCT05375734
- Testing
- Tislelizumab in combination with anlotinib
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Small Cell Lung Cancer
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
To evaluate the efficacy and safety of liposome irinotecan combined with platinum and immune checkpoint inhibitor combined with antirotinib maintenance therapy after first-line induction
- Trial name
- NCT07376499
- Testing
- Liposome Irinotecan, Platinum, Anlotinib
- Volunteers
- 31 people
- Sponsor
- China Medical University, China
Pancreatic Neoplasms
A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer.
It is a trial to assess the efficacy and safety of Penpulimab and Anlotinib in Combination With Nab-paclitaxel Plus Gemcitabine as first-line Therapy in Patients (Pts) With Metastatic Pancreatic Cancer.
- Trial name
- PAAG (NCT05493995)
- Testing
- Penpulimab, Anlotinib, Nab paclitaxel
- Where
- China
- Volunteers
- 66 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Carcinoma, Non-small Cell Lung Cancer
Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative
This is an efficacy and safety study of Anlotinib combined with Sintilimab (IBI 308) in participants with advanced or metastatic non-small cell lung cancer (NSCLC) who have received first-generation EGFR-TKIs resistance along…
- Conditions
- Carcinoma, Non-small Cell Lung Cancer, Lung Neoplasm
- Trial name
- NCT03765775
- Testing
- Sintilimab, Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Hospital of Shijiazhuang City
Non-Small Cell Lung Cancer
The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study
The goal of this clinical trial is to learn about Drug loaded microspheres for bronchial artery chemoembolization (DEB-BACE) combined with anlotinib and adebelimumab in patients with advanced NSCLC after second-line treatment.
- Trial name
- NCT06188650
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ningbo Medical Center Lihuili Hospital
Refractory or Recurrent Neuroblastoma in Children
Efficacy and Safety of Anlotinib, Irinotecan and Temozolomide in the Treatment of Refractory or Recurrent Neuroblastoma in Children: an Open, Single Arm, Single Center, Phase II Clinical Study
Neuroblastoma is an embryonal tumor originated from primitive neural crest cells. It is the most common extracranial solid tumor in children.
- Trial name
- NCT04842526
- Testing
- Anlotinib and irinotecan combined with temozolomide
- Volunteers
- 27 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-Small Cell Lung Cancer
Anlotinib Single Drug as the Maintenance Treatment for Advanced NSCLC
Based on the need of clinical practice of maintenance therapy for advanced NSCLC and the reliable data of third-line treatment for non-small cell lung cancer, the investigators designed a clinical study of anlotinib in…
- Trial name
- NCT03998085
- Testing
- Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Hospital of Jilin University
Nasopharyngeal Carcinoma, Recurrent or Metastatic Nasopharyngeal Carcinoma
Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)
This phase 2 trial studies toripalimab and anlotinib combination treatment in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of at least one line of platinum-based chemotherapy
- Trial name
- NCT04996758
- Testing
- Toripalimab and Anlotinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma
anlotinib was added to TP inductive chemotherapy and definitive chemoradiation in nasopharyngeal carcinoma patients with N2-3 disease with necrosis or/and ECM
- Trial name
- NCT05232552
- Testing
- Anlotinib hydrochloride, induction chemotherapy, concurrent chemoradiation
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Zhejiang Cancer Hospital
Metastatic Triple-Negative Breast Cancer
Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer
The hypothesis of this study is to discover if the capecitabine plus Anlotinib can shrink or slow the growth of pretreated advanced TNBC.
- Trial name
- NCT05089643
- Testing
- Anlotinib, Capecitabine
- Where
- 2 sites in China
- Volunteers
- 35 people
- Sponsor
- Chinese Academy of Medical Sciences
Pancreatic Neoplasm, Metastatic Pancreatic Cancer
Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer
This is an open-label, non-randomized, single-arm phase Ⅱ study aiming to evaluate the efficacy and safety profile of above-mentioned combination strategy in first-line therapy-failed advanced pancreatic cancer.
- Conditions
- Pancreatic Neoplasm, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
- Trial name
- ATNPA (NCT04718701)
- Testing
- Anlotinib+Toripalimab+Nab-paclitaxel
- Where
- China
- Volunteers
- 53 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Hepatocarcinoma
HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection
This is a single center, non-randomized, open, multi-cohort clinical, exploratory Phase II study, to evaluate the efficacy and safety of HAIC combined with TQB2450 and anlotinib as adjuvant therapy in hepatocellular carcinoma…
- Trial name
- NCT05311319
- Testing
- HAIC+TQB2450+Anlotinib
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Fudan University
Advanced Cervical Cancer
Combination Therapy for First Line Treatment of Advanced Cervical Cancer
This is a single center phase 1 trail to observe safety and efficacy of Paclitaxel plus Cisplatin\Carboplatin, PD-L1 antibody Toripalimab and Anlotinib as first-line regimen to treat the patient with metastatic 、persistent or…
- Trial name
- NCT04731038
- Testing
- Anlotinib, Toripalimab, Paclitaxel, Cisplatin/ Carboplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Non-Small Cell Lung Cancer
BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer
This is a Phase Ⅰ/Ⅱa, multi-center, open-label study, aiming to evaluate the safety, tolerability, pharmacokinetic (PK), and efficacy of BR790 in combination with anlotinib in adult participants with advanced NSCLC.
- Trial name
- NCT05715398
- Testing
- BR790+anlotinib
- Volunteers
- 90 people
- Sponsor
- Shanghai Gopherwood Biotech Co., Ltd.